Evidence map›Paper›PMID 40042718›Full record

ReviewJournal of thrombosis and thrombolysis2025

Unveiling the complexities of catheter-related thrombosis: risk factors, preventive strategies, and management.

Hannah L King, Thalia Padilla-Lazos, Akshit Chitkara, Virginia Tan, Genevieve B Benedetti, Aya Agha, Kylee L Martens, Joseph J Shatzel

Abstract readReview
In one paragraph

Review in Journal of thrombosis and thrombolysis, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Risk Factors for Catheter-Related Thrombosis.Journal of clinical medicine · 2026
    Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Hannah L KingDepartment of Medicine, Oregon Health & Science University, Portland, OR, USA. kingh@ohsu.edu.
Thalia Padilla-LazosDepartment of Medicine, Oregon Health & Science University, Portland, OR, USA.
Akshit ChitkaraDepartment of Medical Oncology, Thomas Jefferson University, Philadelphia, PA, USA.
Virginia TanDepartment of Medicine, Oregon Health & Science University, Portland, OR, USA.
Genevieve B BenedettiDepartment of Medicine, Oregon Health & Science University, Portland, OR, USA.
Aya AghaDepartment of Medicine, Oregon Health & Science University, Portland, OR, USA.
Kylee L MartensDivision of Hematology and Medical Oncology, Oregon Health & Science University, Portland, OR, USA.
Joseph J ShatzelDivision of Hematology and Medical Oncology, Oregon Health & Science University, Portland, OR, USA.

Funding

Evaluating the Safety and Efficacy of Targeting the Contact Pathway to Prevent Device Associated Thrombosis.R01HL151367 · NHLBI · OREGON HEALTH & SCIENCE UNIVERSITY · PI SHATZEL, JOSEPH JAMES · 2020 to 2024
$1.5M
NHLBI NIH HHS R01 HL151367
6 · The paper itself

Abstract

Catheter-related deep venous thrombosis (CR-DVT) is a common complication of central venous catheters, however optimal prophylactic and treatment strategies have yet to be fully defined. While the use of anticoagulation for CR-DVT prophylaxis is not routinely recommended, current available data offer heterogeneous results due to small sample size, non-uniform study design, and varying comorbid conditions. Available guidelines for the treatment of CR-DVT generally recommend a limited duration of anticoagulation after catheter removal. If ongoing use is required and the device remains functional, guidelines support anticoagulation throughout the time the catheter remains in place. It is worth acknowledging that data guiding these recommendations is largely derived from observational studies of upper extremity CR-DVT, along with randomized trials of anticoagulation in patients with lower extremity DVT. Therefore, large, randomized controlled trials are desperately needed to define optimal management, especially in patients who are at high risk for bleeding. This review explores the epidemiology and risk factors of CR-DVT, diagnostic, prophylactic and treatment strategies, guideline recommendations, and future advances in the field, including the introduction of novel anticoagulants. With current available evidence, we also conclude with an individualized approach to preventing and managing CR-DVT to assist clinicians who are faced with this common clinical scenario.

Indexed as

AnticoagulantsCentral Venous CathetersVenous ThrombosisHumansPractice Guidelines as TopicRisk FactorsAnticoagulantsCatheter-related thrombosisCentral venous catheterVenous thromboembolism

Identifiers

PMID40042718
PMCPMC13621909

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.